This figure represents 80% more than the year 2022, which was 1.000 million, as reported by BioSim at the 'Biosimilars in the Focus' day for journalists. The amount represents 8% of the system's total pharmaceutical expenditure. Furthermore, the trend indicates that savings will increase and will continue for years, due to the expiration of patents for other biological medicines.
